文献速递细菌感染、耐药与抗菌药物

革兰阳性菌感染:抗菌药物耐药性领导组的研究重点、成果与未来方向

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
PubMed 文献 · Clin Infect Dis · 2017-01-01

抗菌药物耐药性领导组(ARLG)革兰阳性菌委员会聚焦耐甲氧西林金黄色葡萄球菌(MRSA)和耐万古霉素肠球菌(VRE)感染,已批准五项研究项目,涵盖万古霉素药代动力学/药效学、患者结局评估、降阶梯治疗、新生儿重症监护病房管理及VRE菌血症影响,旨在改善患者结局。

要点

  • ARLG重点推进MRSA和VRE感染研究以应对医疗威胁。
  • 已批准项目包括万古霉素剂量对MRSA血流感染结局的影响研究。
  • 研究涵盖MRSA血流感染降阶梯治疗和新生儿重症监护病房管理。

核心结论

  • ARLG革兰阳性菌委员会优先推进MRSA和VRE感染研究以改善患者结局。

研究设计与样本

  • ARLG革兰阳性菌委员会概述其研究重点、成果与挑战,涉及已批准的五项研究项目。

主要发现

  • 已批准项目包括万古霉素药代动力学/药效学研究评价剂量对MRSA血流感染结局的影响。
  • 已批准项目包括定义、测试和验证MRSA血流感染临床试验的创新患者结局评估。
  • 已批准项目包括测试MRSA血流感染降阶梯抗生素治疗新策略。
  • 已批准项目包括新生儿重症监护病房葡萄球菌血流感染管理。
  • 已批准项目包括定义VRE菌血症和达托霉素敏感性对患者结局的影响。

临床怎么用

  • 临床可关注ARLG在MRSA血流感染中万古霉素剂量优化和降阶梯治疗策略的研究进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "step-down" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Doernberg SB, Lodise TP, Thaden JT, et al. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017. PMID: 28350900. doi:10.1093/cid/ciw828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。